natgillin/translations-raw huggingface dataset:
In clinical studies involving 2170 patients treated with DuoTrav the most frequently reported treatment-related adverse reaction was ocular hyperaemia (12.0%)..
U kliničkim studijama, koje su uključile 2170 bolesnika liječenih DuoTravom najčešće zabilježena nuspojava povezana s terapijom bila je hiperemija oka (12,0%).
In clinical studies involving 2314 patients receiving NEVANAC 1 mg/ml the most common adverse reactions were punctate keratitis, foreign body sensation and eyelid margin crusting which occurred in between 0.4% and 0.2% of patients.
U kliničkim ispitivanjima koja su uključila 2314 bolesnika koji su primali NEVANAC 1 mg/ml najučestalije nuspojave bile su punktiformni keratitis, osjećaj stranog tijela i stvaranje krusti na rubu vjeđe što je zabilježeno kod između 0,4% i 0,2 % bolesnika.
In clinical studies involving 2732 patients treated with AZOPT as monotherapy or adjunctive therapy to timolol maleate 5 mg/ml, the most frequently reported treatment-related adverse reactions were: dysgeusia (6.0%) (bitter or unusual taste, see description below) and temporary blurred vision (5.4%) upon instillation, lasting from a few seconds to a few minutes (see also section 4.7).
U kliničkim studijama koje su uključile 2732 bolesnika liječenih AZOPTOM, kao monoterapija ili dodatna terapija s timolol maleatom 5 mg/ml najčešće zabilježene nuspojave povezane s terapijom bile su: disgeuzija (6,0 %) (gorak ili neobičan okus, vidjeti opis niže) i privremeno zamagljen vid (5,4%) nakon ukapavanja, u trajanju od nekoliko sekundi do nekoliko minuta (vidjeti također dio 4.7).
In clinical studies involving 63 paediatric patients between 0 and 12 years of age and 24 adolescents between 12 and 18 years of age with severe haemophilia A no difference in the safety profile of NovoEight was observed between paediatric patients and adults.
U kliničkim ispitivanjima, u kojima su sudjelovala 63 pedijatrijska bolesnika u dobi od 0 do 12 godina i 24 adolescenta u dobi od 12 do 18 godina s teškom hemofilijom A, nije primijećena razlika u sigurnosnom profilu lijeka NovoEight između pedijatrijskih i odraslih bolesnika.
In clinical studies Lonsurf was administered within 1 hour after completion of the morning and evening meals (see section 4.2).
U kliničkim ispitivanjima Lonsurf je primjenjivan unutar 1 sata nakon završetka jutarnjih i večernjih obroka (vidjeti dio 4.2).
In clinical studies low white blood cell counts were seen in 2.1% of Fampyra patients versus 1.9% of patients on placebo.
U kliničkim ispitivanjima opažen je smanjen broj bijelih krvnih stanica u 2,1% bolesnika koji su uzimali Fampyru u usporedbi s 1,9% bolesnika koji su uzimali placebo.
In clinical studies MenACWY-TT-039 and MenACWY-TT-040 a single dose of Nimenrix elicited rSBA responses against the four meningococcal groups, with a response against group C that was comparable to the one elicited by the licensed MenC-CRM vaccine in term of percentages with rSBA titres ≥8 (Table 1).
U kliničkim ispitivanjima MenACWY-TT-039 i MenACWY-TT-040, jednostruka doza Nimenrixa potakla je rSBA odgovore protiv četiri meningokokne grupe, s odgovorom protiv grupe C koji se mogu usporediti s onima koje je postiglo licencirano cjepivo MenC-CRM u smislu postotaka s rSBA titrima ≥8 (Tablica 1).
In clinical studies of 866 treatment-naïve adult patients receiving emtricitabine and tenofovir alafenamide with elvitegravir and cobicistat as the fixed-dose combination tablet elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide (as fumarate) 10 mg (E/C/F/TAF) through 96 weeks, the most frequently reported adverse reactions were diarrhoea (7%), nausea (10%), and headache (6%).
U kliničkim ispitivanjima u kojima je 866 odraslih bolesnika koji prethodno nisu bili liječeni primalo emtricitabin i tenofoviralafenamid s elvitegravirom i kobicistatom kao fiksnu kombinaciju elvitegravira 150 mg/kobicistata 150 mg/emtricitabina 200 mg/tenofoviralafenamida (u obliku fumarata) 10 mg u jednoj tableti (E/C/F/TAF) tijekom 96 tjedana, najčešće zabiljeţene nuspojave bile su proljev (7%), mučnina (10%) i glavobolja (6%).
In clinical studies of Genvoya, increases in serum creatinine occurred by Week 2 of treatment and remained stable through 96 weeks.
U kliničkim ispitivanjima lijeka Genvoya porast serumskog kreatinina nastupio je do 2. tjedna liječenja i ostao stabilan tijekom 96 tjedana.
In clinical studies of patients with Non-Hodgkin’s lymphoma, the addition of rituximab to a mobilisation regimen of plerixafor and G-CSF did not impact patient safety or CD34+ cell yield.
U kliničkim ispitivanjima bolesnika s ne-Hodgkinovim limfomom dodavanje rituksimaba protokolu mobilizacije pleriksaforom i G-CSF-om nije utjecalo na sigurnost bolesnika niti na broj CD34+ stanica.
In clinical studies of prolonged-release exenatide, approximately 45 % of patients had low titre antibodies to exenatide at study endpoint.
U kliničkim ispitivanjima eksenatida s produljenim oslobađanjem otprilike 45% bolesnika imalo je nizak titar protutijela na eksenatid na ishodu ispitivanja.
In clinical studies of RA, 775 patients treated with daily Kineret doses of 30mg, 75mg, 150mg, 1mg/kg or 2mg/kg, there was an increase of 2.4% to 5.3% in total cholesterol levels 2 weeks after start of Kineret treatment, without a dose-response relationship.
U kliničkim ispitivanjima reumatoidnog artritisa u 775 bolesnika liječenih s dnevnim dozama Kinereta od 30 mg, 75 mg, 150 mg ,1 mg/kg ili 2 mg/kg , dva tjedna nakon početka liječenja Kineretom došlo je do povećanja razine ukupnog kolesterola za 2,4% do 5,3%, neovisno o dozi.
In clinical studies of RA, 775 patients treated with daily Kineret doses of 30mg, 75mg, 150mg, 1mg/kg or 2mg/kg, there was an increase of 2.4% to 5.3% in total cholesterol levels 2 weeks after start of Kineret treatment, without a dose-response relationship.
U kliničkim ispitivanjima reumatoidnog artritisa u 775 bolesnika liječenih s dnevnim dozama Kinereta od 30 mg, 75 mg, 150 mg, 1 mg/kg ili 2 mg/kg, dva tjedna nakon početka liječenja Kineretom došlo je do povećanja razine ukupnog kolesterola za 2,4% do 5,3%, neovisno o dozi.
In clinical studies of secondarily infected open wounds, the efficacy of retapamulin was inadequate in patients with infections caused by MRSA.
U kliničkim ispitivanjima sekundarno inficiranih otvorenih rana, djelotvornost retapamulina nije bila primjerena u bolesnika s infekcijama uzrokovanima MRSA-om.
In clinical studies of sunitinib and from post-marketing experience, seizures have been observed in subjects with or without radiological evidence of brain metastases.
U kliničkim ispitivanjima sunitiniba i u razdoblju nakon stavljanja lijeka u promet zabilježeni su slučajevi napadaja u bolesnika koji su imali, kao i u onih koji nisu imali radiološki potvrđene metastaze u mozgu.
In clinical studies of treatment with romiplostim in patients with MDS, cases of transient increases in blast cell counts were observed and cases of MDS disease progression to AML were reported.
U kliničkim ispitivanjima liječenja romiplostimom u bolesnika s MDS, primijećeni su slučajevi prolaznog porasta broja stanica blasta i prijavljeni su slučajevi progresije bolesti MDS u AML.
In clinical studies of treatment-experienced patients, rash, irrespective of causality, was more commonly observed with regimens containing ISENTRESS and darunavir compared to those containing ISENTRESS without darunavir or darunavir without ISENTRESS.
U kliničkim ispitivanjima u prethodno liječenih bolesnika osip je, bez obzira na uzrok, češće zapažen u bolesnika čija je terapija uključivala ISENTRESS i darunavir nego u onih koji su primali ISENTRESS bez darunavira ili darunavir bez lijeka ISENTRESS.
In clinical studies patients converted from twice daily Prograf were converted to Envarsus at 1: 0.85(mg:mg).
U kliničkim ispitivanjima, bolesnici su prešli s Prografa, dva puta dnevno, na Envarsus u omjeru 1: 0,85(mg: mg).
In clinical studies Rasilez has not been investigated in hypertensive patients with severe renal impairment (serum creatinine ≥ 150 μmol/l or 1.70 mg/dl in women and ≥ 177 μmol/l or 2.00 mg/dl in men and/or estimated GFR < 30 ml/min/1.73 m2), history of dialysis, nephrotic syndrome or renovascular hypertension.
U kliničkim ispitivanjima Rasilez nije ispitivan u hipertenzivnih bolesnika s teškim oštećenjem bubrežne funkcije (kreatinin u serumu ≥150 μmol/l ili 1,70 mg/dl u žena, te ≥177 μmol/l ili 2,00 mg/dl u muškaraca i/ili procijenjena brzina glomerularne filtracije (GFR) <30 ml/min/1,73 m2), dijalizom, nefrotskim sindromom ili renovaskularnom hipertenzijom u anamnezi.
In clinical studies seizures were observed in 1.4% of cinacalcet treated patients and 0.7% of placebo- treated patients.
U kliničkim studijama napadaji su opaženi u 1,4 % bolesnika liječenih sinakalcetom i 0,7 % bolesnika u placebo grupi.
In clinical studies seizures were observed in 1.4% of Mimpara treated patients and 0.7% of placebo-treated patients.
U kliničkim studijama napadaji su opaženi u 1,4 % bolesnika liječenih Mimparom i 0,7 % bolesnika u placebo grupi.
In clinical studies that enrolled girls and women aged from 10 up to 72 years (of which 79.2% were aged 10-25 years at the time of enrolment), Cervarix was administered to 16,142 females whilst 13,811 females received control.
U kliničkim ispitivanjima koja su uključivala djevojčice i žene u dobi od 10 do 72 godine (od kojih je 79,2% u vrijeme uključivanja bilo u dobi 10-25 godina), Cervarix je primijenjen u 16 142 djevojčice i žene, dok je 13 811 djevojčica i žena primilo kontrolno cjepivo.
In clinical studies that evaluated reactogenicity in adults aged 18 years and above who received two 0.5 ml doses of Pandemrix (H1N1)v, higher rates of general solicited symptoms (such as fatigue, headache, arthralgia, myalgia, shivering, sweating and fever) were observed after the second dose compared to the first dose.
U kliničkim ispitivanjima reaktogenosti u odraslih osoba starijih od 18 godina, koje su primile dvije doze cjepiva Pandemrix (H1N1)v od 0,5 ml, opći simptomi (poput umora, glavobolje, artralgije, mijalgije, drhtanja, znojenja i vrućice) zamijećene su u većim stopama nakon druge primljene doze, nego nakon prve doze.
In clinical studies that evaluated the immunogenicity of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 in subjects aged 18-60 years the anti-haemagglutinin (anti- HA) antibody responses were as follows:
U kliničkim ispitivanjima imunogenosti AS03-adjuvantiranih cjepiva koja sadrže 3,75 µg HA dobivenog iz soja A/Vietnam/1194/2004 u ispitanika u dobi od 18 do 60 godina, odgovori anti- hemaglutinin protutijela (anti-HA) bili su sljedeći:
In clinical studies the mean apparent clearance of exenatide is 9 l/h and the mean terminal half-life is 2.4 h.
U kliničkim ispitivanjima prosječan prividni klirens ekstanatida iznosi 9 l/h, a prosječan terminalni poluvijek 2,4 sata.
In clinical studies there was no age-related difference in the efficacy or safety profiles of alendronate.
U kliničkim ispitivanjima nisu utvrđene razlike u djelotvornosti ili sigurnosti primjene alendronata vezane za dob.
In clinical studies these side effects were stopped immediately upon intravenous administration of a standard dose of diazepam.
U kliničkim su ispitivanjima ove reakcije odmah prekinute intravenoznom primjenom standardne doze diazepama.
In clinical studies used for registration, a total of 999 HAE attacks have been treated with 30 mg Firazyr administered subcutaneously by a healthcare professional.
U kliničkim ispitivanjima korištenim za registraciju, ukupno 999 napadaja nasljednog angioedema (HAE) liječeno je s 30 mg Firazyra koji je potkožno primijenio zdravstveni djelatnik.
In clinical studies using Lymphoseek, study investigators employed a threshold rule for positive localisation of technetium Tc 99m that was estimated using the background radioactivity counts plus three standard deviations from the mean background count level (i.e., the three-sigma rule, representing >99.7% probable difference from background) [see Table 4].
U kliničkim ispitivanjima lijeka Lymphoseek, ispitivači su koristili pravilo praga za pozitivnu lokalizaciju tehnecija Tc 99m koji je procijenjen zbrajanjem pozadinske radioaktivnosti plus tri standardne devijacije prosječnog pozadinskog broja (primjerice, tri sigma pravilo, predstavljajući >99,7% izglednu razliku u odnosu na pozadinu) [vidjeti tablicu 4.].
In clinical studies where once-daily doses of up to 100 mg (10 times the maximum recommended human dose) were administered for 2 weeks in healthy subjects and type 2 diabetes subjects, the incidence of hypoglycaemia was slightly higher than placebo and was not dose-related.
U kliničkim ispitivanjima u kojima su u zdravih ispitanika i u bolesnika sa šećernom bolešću tipa 2 tijekom tjedna primjenjivane doze do 100 mg jednom na dan (10 puta više od preporučene doze u ljudi) incidencija hipoglikemije bila je nešto viša nego u ispitanika koji su primali placebo i nije bila povezana s dozom.
In clinical studies with 24 months follow-up in chronic phase CML, 10 of the 215 imatinib-intolerant patients had the same grade 3 or 4 non-haematologic toxicity with SPRYCEL as they did with prior imatinib; 8 of these 10 patients were managed with dose reduction and were able to continue SPRYCEL treatment.
U kliničkim ispitivanjima s 24 mjeseca praćenja KML u kroničnoj fazi, 10 od 215 bolesnika koji nisu podnosili imatinib imalo je iste nehematološke toksične reakcije 3. ili 4. stupnja prilikom primjene lijeka SPRYCEL kao i prethodno tijekom liječenja imatinibom; u 8 od navedenih 10 bolesnika reakcije su se povukle nakon smanjenja doze i liječenje lijekom SPRYCEL moglo se nastaviti.
In clinical studies with a limited number of elderly patients, there was no relevant age-related difference with regard to the efficacy or safety profiles of lipegfilgrastim.
U kliničkim ispitivanjima s ograničenim brojem starijih bolesnika, nije bilo važne razlike u profilu djelotvornosti i sigurnosti lipegfilgrastima povezane s dobi.
In clinical studies with adults who received Pandemic influenza vaccine H5N1 MedImmune, the most common side effects were headache and upper respiratory tract infection (inflammation of the nose, throat, and sinuses).
U kliničkim ispitivanjima s odraslim osobama koje su primile Pandemijsko cjepivo protiv influence H5N1 MedImmune, najčešće nuspojave bile su glavobolja i infekcija gornjih dišnih puteva (upala nosa, grla i sinusa).
In clinical studies with Aerius, the following side effects were reported as: Children
U kliničkim ispitivanjima s lijekom Aerius, sljedeće nuspojave bile su prijavljene kao: Djeca
In clinical studies with Aerius, the following side effects were reported as: Common: the following may affect up to 1 in 10 people
U kliničkim ispitivanjima s lijekom Aerius, sljedeće nuspojave bile su prijavljene kao: Česte: sljedeće nuspojave mogu se javiti u do 1 na 10 osoba
In clinical studies with axitinib for the treatment of patients with RCC, cardiac failure events (including cardiac failure, cardiac failure congestive, cardiopulmonary failure, left ventricular dysfunction, ejection fraction decreased, and right ventricular failure) were reported (see section 4.8).
U kliničkim ispitivanjima aksitiniba u terapiji bolesnika s RCC-om prijavljeni su događaji zatajenja srca (uključujući zatajenje srca, kongestivno zatajenje srca, kardiopulmonalno zatajenje, poremećaj funkcije lijeve klijetke, smanjenje ejekcijske frakcije i zatajenje desne klijetke) (vidjeti dio 4.8).
In clinical studies with axitinib, events of gastrointestinal perforation and fistulas were reported (see section 4.8).
U kliničkim ispitivanjima aksitiniba prijavljene su gastrointestinalne perforacije i fistule (vidjeti dio 4.8).
In clinical studies with axitinib, events of PRES were reported (see section 4.8).
U kliničkim ispitivanjima aksitiniba prijavljeni su slučajevi PRES-a (vidjeti dio 4.8).
In clinical studies with Azomyr, the following side effects were reported as: Children
U kliničkim ispitivanjima s lijekom Azomyr, sljedeće nuspojave bile su prijavljene kao: Djeca
In clinical studies with Azomyr, the following side effects were reported as: Common: the following may affect up to 1 in 10 people
U kliničkim ispitivanjima s lijekom Azomyr, sljedeće nuspojave bile su prijavljene kao: Česte: sljedeće nuspojave mogu se javiti u do 1 na 10 osoba
In clinical studies with ceritinib, diarrhoea, nausea and vomiting have been very commonly reported; grade 3-4 events of diarrhoea, nausea or vomiting were reported in 12.2% of patients.
U kliničkim ispitivanjima s ceritinibom, proljev, mučnina i povraćanje prijavljeni su vrlo često; slučajevi proljeva, mučnine ili povraćanja stupnja 3-4 bili su prijavljeni u 12,2% bolesnika.
In clinical studies with crizotinib in patients with either ALK-positive or ROS1-positive NSCLC (N=1722), Grade 4 visual field defect with vision loss has been reported in 4 (0.2%) patients.
U kliničkim ispitivanjima s krizotinibom kod bolesnika s ALK pozitivnim ili ROS1-pozitivnim NSCLC-om (N=1772), ispad vidnog polja stupnja 4 s gubitkom vida prijavljen je kod 4 (0,2 %) bolesnika.
In clinical studies with crizotinib in patients with either ALK-positive or ROS1-positive NSCLC, Grade 3 or 4 neutropenia has been very commonly (12%) reported.
U kliničkim ispitivanjima s krizotinibom u bolesnika s ALK-pozitivnim ili ROS1-pozitivnim NSCLC- om, neutropenija stupnja 3 ili 4 vrlo često je prijavljivana (12%).
In clinical studies with crizotinib, events of gastrointestinal perforations were reported.
U kliničkim ispitivanjima s krizotinibom, prijavljene su gastrointestinalne perforacije.
In clinical studies with desloratadine, the following side effects were reported as: Common (the following may affect up to 1 in 10 people):
U kliničkim ispitivanjima s loratadinom, sljedeće nuspojave bile su prijavljene kao: Česte (sljedeće nuspojave mogu se javiti u do 1 na 10 osoba)
In clinical studies with desloratadine, the following side effects were reported as: Common: the following may affect up to 1 in 10 people
U kliničkim ispitivanjima s desloratadinom, sljedeće nuspojave bile su prijavljene kao: Česte: sljedeće nuspojave mogu se javiti u do 1 na 10 osoba:
In clinical studies with desloratadine, the following side effects were reported as: Common: the following may affect up to 1 in 10 people
U kliničkim ispitivanjima s desloratadinom, sljedeće nuspojave bile su prijavljene kao: Česte: sljedeće nuspojave mogu se javiti u najviše 1 na 10 osoba
In clinical studies with doses up to 700 mg/m2 given every 2 weeks the safety profile was consistent with that described in section 4.8.
U kliničkim ispitivanjima s dozama do 700 mg/m2 tjelesne površine koje su se davale svaka 2 tjedna sigurnosni profil u skladu je s profilom opisanim u dijelu 4.8.
In clinical studies with filgrastim administration to HIV patients, the only adverse effects consistently considered to be related to filgrastim administration were musculoskeletal pain, bone pain and myalgia.
U kliničkim ispitivanjima primjene filgrastima bolesnicima s HIV infekcijom jedine nuspojave za koje se dosljedno smatralo da su povezane s liječenjem filgrastimom bile su mišićno-koštana bol, koštana bol i mialgija.
In clinical studies with Gazyvaro, doses ranging from 50 mg up to and including 2,000 mg per infusion have been administered.
U kliničkim ispitivanjima lijeka Gazyvaro primjenjivane su doze u rasponu od 50 mg do, i uključujući, 2000 mg po infuziji.
In clinical studies with GONAL-f comparing r-hFSH (follitropin alfa) and urinary FSH in ART (see table 3 below) and in ovulation induction, follitropin alfa was more potent than urinary FSH in terms of a lower total dose and a shorter treatment period needed to trigger follicular maturation.
U kliničkim ispitivanjima GONAL-f u kojima se uspoređivao r-hFSH (folitropin alfa) i urinarni FSH kod MPO (vidjeti tablicu 3 u nastavku) i kod indukcije ovulacije, folitropin alfa bio je potentniji od urinarnog FSH u smislu niže ukupne doze i kraćeg razdoblja liječenja potrebnog da se potakne sazrijevanje folikula.
In clinical studies with infliximab in which 5,780 patients were treated, representing 5,494 patient years, 5 cases of lymphomas and 26 non-lymphoma malignancies were detected as compared with no lymphomas and 1 non-lymphoma malignancy in 1,600 placebo-treated patients representing
U kliničkim ispitivanjima s infliksimabom u kojima je liječeno 5780 bolesnika, što predstavlja ukupno 5494 bolesnik-godina, otkriveno je 5 slučajeva limfoma i 26 slučajeva zloćudnih bolesti koje nisu bili limfomi, u odnosu na niti jedan slučaj limfoma i jedan slučaj zloćudne bolesti koja nije bila limfom u 1600 bolesnika koji su primali placebo, što predstavlja ukupno 941 bolesnik-godinu.
In clinical studies with Kyprolis, cardiac failure was reported in approximately 7% of subjects (< 5% of subjects had grade ≥ 3 events), myocardial infarction was reported in approximately 2% of subjects (< 1.5% of subjects had grade ≥ 3 events) and myocardial ischaemia was reported in approximately 1% of subjects (< 1% of subjects had grade ≥ 3 events).
U kliničkim ispitivanjima lijeka Kyprolis, zatajenje srca je bilo prijavljeno u otprilike 7% ispitanika (< 5% ispitanika imalo je događaj 3. ili višeg stupnja), infarkt miokarda je bio prijavljen u otprilike 2% ispitanika (< 1,5% ispitanika imalo je događaj 3. ili višeg stupnja), a ishemija miokarda je bila prijavljena u otprilike 1% ispitanika (< 1% ispitanika imalo je događaj 3. ili višeg stupnja).
In clinical studies with Neoclarityn, the following side effects were reported as: Children
U kliničkim ispitivanjima s lijekom Neoclarityn, sljedeće nuspojave bile su prijavljene kao: Djeca
In clinical studies with Neoclarityn, the following side effects were reported as: Common: the following may affect up to 1 in 10 people
U kliničkim ispitivanjima s lijekom Neoclarityn, sljedeće nuspojave bile su prijavljene kao: Česte: sljedeće nuspojave mogu se javiti u do 1 na 10 osoba
In clinical studies with patients with resistance or intolerance to prior imatinib therapy, it was recommended that treatment with imatinib be discontinued at least 7 days before starting treatment with SPRYCEL.
U kliničkim se ispitivanjima s bolesnicima koji ne podnose ili su otporni na prethodnu terapiju imatinibom, preporučivalo da liječenje imatinibom bude prekinuto najmanje 7 dana prije početka liječenja lijekom SPRYCEL.
In clinical studies with pazopanib haemorrhagic events have been reported (see section 4.8).
U kliničkim ispitivanjima pazopaniba zabilježeni su slučajevi krvarenja (vidjeti dio 4.8).
In clinical studies with pazopanib, events of QT prolongation and Torsade de Pointes have occurred (see section 4.8).
U kliničkim ispitivanjima pazopaniba zabilježeni su slučajevi produljenja QT intervala i Torsade de Pointes (vidjeti dio 4.8).
In clinical studies with pazopanib, myocardial infarction, ischemic stroke, and transient ischemic attack were observed (see section 4.8).
U kliničkim ispitivanjima pazopaniba zabilježeni su slučajevi infarkta miokarda, ishemičnog moždanog udara i tranzitorne ishemične atake (vidjeti dio 4.8).
In clinical studies with psoriasis patients, dimethyl fumarate affected lymphocyte phenotypes through a down-regulation of pro- inflammatory cytokine profiles (TH1, TH17), and biased towards anti-inflammatory production (TH2).
U kliničkim ispitivanjima u bolesnika s psorijazom, dimetilfumarat je utjecao na fenotipove limfocita preko smanjenja profila proupalnih citokina (TH1, TH17) te je bio pristran prema protuupalnoj produkciji (TH2).
In clinical studies with rotigotine, syncope has been observed at a rate that was similar to that observed in patients treated with placebo.
U kliničkim ispitivanjima rotigotinom primjećena je sinkopa sa stopom sličnom onoj primjećenoj u bolesnika koji su primali placebo.
In clinical studies with rotigotine, syncope has been observed at a rate that was similar to that observed in patients treated with placebo.
U kliničkim ispitivanjima s rotigotinom primijećena je sinkopa sa stopom sličnom onoj primijećenoj u bolesnika koji su primali placebo.